INTERVIEW: Rabbi Moshe Margaretten Speaks on TrumpRX Moments Before Rollout

The Trump administration is set to begin rolling out TrumpRX Thursday, a pharmaceutical initiative that advocacy leaders are calling a “landmark” achievement in the fight to make infertility treatments affordable for American families.

Rabbi Moshe Margaretten, founder and president of the Tzedek Association, who has been a driving force behind efforts to include fertility treatments in the program, shared his excitement, in an exclusive statement to Belaaz, saying: “Today is an extraordinarily exciting and meaningful day for countless families across America,” Margaretten said. “Three years ago, Tzedek launched a determined effort to confront one of the most painful and overlooked challenges faced by couples, the crushing cost of infertility treatment.”

The advocacy organization initially pursued legislative solutions through Congress, but pivoted strategy when President Trump secured the Republican nomination. Margaretten explained that the shift reflected confidence in executive action as a faster path to results.

“From the moment President Trump became the nominee, we recognized that the fastest and most impactful path forward would be through executive action,” he said. “Based on everything we witnessed throughout his first term, we believed he could once again be the one to move this issue in a real and historic way.”

According to Margaretten, Tzedek has been working closely with the White House for the past year on detailed proposals to address infertility treatment costs. “After sustained engagement, detailed proposals, and many conversations, that belief has now been powerfully validated,” he stated.

He praised the administration’s responsiveness to the issue. “The President, the Chief of Staff, the Domestic Policy Council, and the entire administration are fully tuned in, responsive, and genuinely committed to ensuring that no couple is ever forced to think twice about whether they can afford the treatments needed to bring a child into the world.”

Margaretten characterized the TrumpRX launch as the first step in a broader effort. “With the launch of TrumpRX tonight, we are seeing the first major breakthrough of that effort. This is not only progress, it is a landmark on the path toward making fertility treatment accessible at the lowest possible cost, and ultimately fully covered.”

Margaretten concluded with optimism about future developments: “This is only the beginning. We are energized, deeply grateful, and looking forward to sharing even more good news very soon bez”H.”

Infertility affects approximately one in eight couples in the United States, with treatments often costing tens of thousands of dollars and rarely covered by insurance. The TrumpRX initiative represents a significant policy development in addressing these financial barriers, though specific details about coverage levels and implementation timelines were not immediately available.